Daniel Sieveking holds a Bachelor of Science with First Class Honours in medical microbiology and immunology from the University of New South Wales. Daniel’s doctoral studies were undertaken at the Heart Research Institute and the University of Sydney and focused on the role of male sex hormones in vascular biological processes.
Following the completion of his PhD, Daniel was a postdoctoral fellow at Stanford University in the School of Medicine, where his research focused on cellular reprogramming, induced pluripotent stem cells (iPSCs) and their application in regenerative medicine. Daniel was awarded a CJ Martin Postdoctoral Fellowship from the Australian National Health and Medical Research Council to undertake this research.
Daniel has presented his research at various international conferences and had his work published in a number of peer-reviewed publications.
Daniel assists a variety of local and international clients in the drafting and prosecution of patent applications primarily in the areas of biotechnology and pharmaceuticals. He is also actively involved in patent opposition matters, obtaining extensions of term for pharmaceutical patents and providing advice on patentability, and the infringement and validity of patents.
He is a member of The Institute of Patent and Trade Mark Attorneys of Australia, the Intellectual Property Society of Australia and New Zealand, AusBiotech and the Standing Committee on Pharma at AIPPI.